| Identification | Back Directory | [Name]
Inulanolide A | [CAS]
888941-86-4 | [Synonyms]
Inulanolide A
(3S,3aR,3'aS,4R,6'S,7aS,8'aR,9'R,10'aR,11'R)-11'-(Acetyloxy)-5-[(1R)-4-(acetyloxy)-1-methylbutyl]-3a,3'a,4,4',6',7,7a,9',10',10'a-decahydro-4-hydroxy-5',6,9'-trimethyl-3'-methylene-spiro[benzofuran-3(2H),7'(8'H)-[6,8a]methano[8aH]benzo[4,5]cyclohepta[1,2-b]furan]-2,2'(3'H)-dione | [Molecular Formula]
C34H44O9 |
| Hazard Information | Back Directory | [Description]
Inulanolide A has potent cytotoxicity.
Inulanolide A is a novel NFAT1 and MDM2 dual targeting agent and may be a clinical candidate for breast cancer therapy. | [target]
Mdm2 | p53 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
www.biorbyt.com |
|